The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:2406-2407 May 29, 2008 Number 22
NextNext

Local Paclitaxel Delivery in Peripheral Vascular Disease

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Tepe, G.
-PubMed Citation
To the Editor: With regard to the Local Taxane with Short Exposure for Reduction of Restenosis in Distal Arteries (THUNDER) trial, reported by Tepe et al. (Feb. 14 issue),1 paclitaxel, like endovascular brachytherapy, may postpone rather than inhibit restenosis. Morphologic follow-up for more than 6 months therefore seems desirable. The usefulness of relying on target-lesion revascularization as an end point in studies of peripheral vascular disease is debatable,2 particularly in an unblinded trial, such as the THUNDER study, which might be prone to bias. Indeed, a 6-month reintervention rate of 37% in the control group (mean lesion length, 74 mm) . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.